Otsuka’s Abilify receives NICE backing for bipolar I disorder

Otsuka Pharmaceuticals has received a draft recommendation for its drug Abilify to be used in the treatment of adolescent NHS patients with bipolar I disorder.

The National Institute for Health and Care Excellence (NICE) has published draft guidance endorsing the drug for treating moderate to severe manic episodes in adolescents aged 13 and older.

Moreover, the independent committee decided that an appraisal consultation document was not needed, meaning these recommendations could go straight to the final draft or final appraisal determination stage.

Acute manic episodes associated with bipolar disorder can cause irritability, poor concentration, a diminished need for sleep and poor temper control, resulting in a huge impact on the patient and their family.

Professor Carole Longson, director at NICE's Centre for Health Technology Evaluation, said: "It is really important that manic episodes are treated quickly and effectively so that young people and their families can return to normal in terms of schooling, work and family life as quickly as possible."

Abilify is also intended for use in the treatment of other mental conditions such as depression, schizophrenia and irritability associated with autism.